Assenagon Asset Management S.A. Iovance Biotherapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 18, 2023	SELL	$5.53 - $8.22 $38 - $57	-7 Reduced 0.02%	32,047 $195,000
Q4 2022 Jan 12, 2023	SELL	$5.62 - $10.0 $365 - $650	-65 Reduced 0.2%	32,054 $205,000
Q2 2022 Jul 27, 2022	SELL	$6.38 - $18.33 $523 - $1,503	-82 Reduced 0.25%	32,119 $355,000
Q4 2021 Feb 01, 2022	SELL	$16.55 - $27.63 $23.6 Million - $39.4 Million	-1,425,107 Reduced 97.79%	32,201 $615,000
Q3 2021 Oct 19, 2021	SELL	$20.35 - $26.63 $456,063 - $596,804	-22,411 Reduced 1.51%	1,457,308 $35.9 Million
Q2 2021 Jul 15, 2021	BUY	$16.33 - $33.07 $23.6 Million - $47.7 Million	1,443,340 Added 3967.51%	1,479,719 $38.5 Million
Q1 2021 Apr 26, 2021	BUY	$28.67 - $52.59 $1.04 Million - $1.91 Million	36,379 New	36,379 $1.15 Million

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.48B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.